Anebulo Pharmaceuticals
Dr. Calloway is an analyst and partner at 22NW, LP, a Seattle-based value fund specializing in small and microcap investments with a multi-year investment horizon, where he has been employed since June 2021. Dr. Calloway is the lead for 22NW, LP’s biotechnology, pharmaceutical and other healthcare investments, including Anebulo Pharmaceuticals, Inc. Prior to that, Dr. Calloway was the Associate Director of Healthcare Research for Edison Group from December 2015 to June 2021. Dr. Calloway is also on the board of Lifecore Biomedical, an integrated CDMO company specializing in sterile injectables. He has a Ph.D. in Chemistry and Chemical Biology from Cornell University, a Masters of Science in Chemistry from Columbia and completed a post-doctoral study in neuroscience at Weill Cornell Medical School. He has 10 scientific publications in the areas of physical chemistry, biochemistry and neuroscience.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Anebulo Pharmaceuticals
Anebulo was founded with the intention of developing disruptive treatments for substance use disorders, such as cannabinoid intoxication and the broader addiction landscape.